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Abstract
Purpose of Review There is no consensus on the best technol-
ogy to be employed for tracheal replacement. One particularly
promising approach is based upon tissue engineering and in-
volves applying autologous cells to transplantable scaffolds.
Here, we present the reported pre-clinical and clinical data
exploring the various options for achieving such seeding.
Recent Findings Various cell combinations, delivery strate-
gies, and outcome measures are described. Mesenchymal
stem cells (MSCs) are the most widely employed cell type
in tracheal bioengineering. Airway epithelial cell luminal
seeding is also widely employed, alone or in combination with
other cell types. Combinations have thus far shown the
greatest promise. Chondrocytes may improve mechanical out-
comes in pre-clinical models, but have not been clinically
tested. Rapid or pre-vascularization of scaffolds is an impor-
tant consideration. Overall, there are few published objective
measures of post-seeding cell viability, survival, or overall
efficacy.
Summary There is no clear consensus on the optimal cell-
scaffold combination and mechanisms for seeding.
Systematic in vivo work is required to assess differences be-
tween tracheal grafts seeded with combinations of clinically
deliverable cell types using objective outcome measures, in-
cluding those for functionality and host immune response.
Keywords Trachea . Tissue engineering . Autologous cell
seeding . Pre-clinical models . Clinical translation
Introduction
Treatment outcomes for long-segment tracheal disease in chil-
dren have been steadily improving over the last decade, due
mostly to advances in the slide tracheoplasty technique and
improvements in post-operative care [1]. However, there re-
mains a small subset of patients with extensive disease who
cannot be managed by conventional means, as surgical resec-
tion would lead to an unacceptable level of tension on the
anastomotic joins and failure of ventilation from kinking of
the carina [2]. Endoscopic or conventional open surgery, such
as end-to-end resection, can manage the majority of adult
patients with acquired or idiopathic tracheal stenosis [3, 4].
These patients are those whose tracheal disease exceeds
50% of the total tracheal length in adults (or 30% of the total
length in children) [5, 6], those whose primary reconstruction
is unsuccessful, or those whose underlying tracheal disease
recurs. In adults, voice outcomes from resection surgery are
often suboptimal and recurrent stenosis is common [7]. In
these, sometimes life-threatening and life-changing,
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circumstances, part- or whole-organ scale replacement of the
trachea could be life-transforming or life-saving.
Interest in the field of regenerative medicine has grown
exponentially in recent decades, and the subfield of tissue
engineering sits at the intersection between cell biology, ma-
terials science, and engineering. In contrast to passive im-
plants and medical constructs that are already widely
employed across human and veterinary medicine, tissue-
engineeredmedical devices aim to functionally repair, replace,
or regenerate living tissue [8, 9]. The basic principle behind
tissue engineering is to manufacture a biocompatible scaffold
that supports the growth and differentiation of the recipient’s
cells, to create a functioning neo-organ upon implantation
[10]. Personalized scaffolds created in this way should not
evoke conventional immune rejection responses and can thus
be implanted without the need for immunosuppressive medi-
cation. In children, functional regeneration and remodeling of
the replaced tissue might obviate the risk of the child outgrow-
ing the transplant and needing serial re-transplantation.
The trachea was initially considered, perhaps naively, to be
a convenient Bstarter organ^ on which to concentrate tissue
engineering efforts, due to its relatively simple tubular anato-
my and Bbasic^ primary function of passive air conduction to
the lungs [11]. Given the lack of alternative treatment options
in end-stage (often emergent) tracheal disease, the use of ex-
perimental therapies raises fewer potential ethical objections
than in other clinical areas [12]. Regenerative approaches to
tracheal reconstruction have, therefore, been in the forefront of
the movement to create tissue-engineered solutions to organ
and tissue replacement, and compassionate use clinical cases
in both adults [13, 14] and in children [15, 16••] have been
reported. However, at this stage, there remain significant sci-
entific and surgical hurdles to wider testing in clinical trials
and general clinical acceptance of this technology [17]. As
such, it is vital that some criteria are internationally adopted
to move this field forward. We propose the following criteria
be considered for this purpose: (i) the internationally accumu-
lated body of pre-clinical and clinical data is appraised and
taken into account in the planning of future work, with adop-
tion of an international registry; (ii) both basic and translation-
al research should be carefully evaluated and should be con-
stantly reviewed by independent peers; (iii) patients should be
centralized into fewer centers to accumulate appropriate expe-
rience; (iv) careful, ethical patient selection is required, using
alternative conventional techniques wherever these remain
possible; and (v) once consensus is reached on the best strat-
egy for scaffold procurement, preparation, and cell seeding,
formal, ethically approved and nationally/internationally reg-
ulated clinical trials are required to demonstrate superiority
over conventional treatments. An open-minded, collaborative,
and constructive approach is required to improve airway re-
pair and replacement in this rare patient group with life-
changing and life-threatening structural airway abnormalities.
Here, we critically review recent advances in the field, fo-
cusing on the application of autologous cells in tissue-
engineered tracheal replacements and, specifically, on the
use of such constructs in clinically relevant in vivo orthotopic
transplantation models.
Scaffold Options for Tracheal Tissue Engineering
The ideal tissue-engineered scaffold for airway transplantation
would be capable of promoting exogenous cell engraftment
and endogenous cell ingrowth, proliferation, and appropriate
differentiation, while maintaining a patent airway. Moreover,
this scaffold must be able to promote the rapid establishment
and support of vasculature, to allow cell survival and func-
tional differentiation [12]. To date, two main scaffold strate-
gies have been proposed in tracheal tissue engineering: (1)
decellularized human cadaveric donor tissue or (2) synthetic
scaffolds created de novo. The overriding principle behind the
production and use of decellularized biological scaffolds from
cadaveric tissue is the removal of all cellular components that
are thought to be capable of eliciting an allo-rejection response
if left behind. This may be achieved by physical, mechanical,
and chemical methods [18–20] and is intended to preserve the
underlying extracellular matrix (ECM), including its critical
microanatomy, as well as its structural and signaling compo-
nents. Cells are removed or their immunologically active pro-
teins denatured [21–24] before the scaffold is seeded with
autologous cells from the recipient, which, as Bself,^ are inca-
pable of eliciting an immune response in the patient. Such
scaffolds have been shown to retain a wealth of specific mo-
lecular cues and anchorage points to support patient cell in-
growth, survival, and differentiation [25]. There is also evi-
dence that implanted decellularized tissue can downregulate
local immune responses, leading to a Bremodeling^ of im-
mune cell phenotypes [26]. The main drawbacks to the use
of decellularized cadaveric tissue scaffolds are a continued
reliance on donor organ supply, which may be ameliorated if
animal sources are validated for use in the future, and the
potential removal of ECM signals, be they physical or chem-
ical, which are needed for constructive remodeling to take
place [27]. Moreover, if the decellularization process substan-
tially changes the biomechanical integrity of the scaffold, the
endogenous remodeling by patient cells may be suboptimal
since mesenchymal cell differentiation is known to be affected
by substrate Bstiffness^ [28]. Additionally, there remains a
possibility that despite decellularization, scaffolds can still
elicit an adverse immune response, either in the form of
damage-associated molecular pattern proteins (DAMPs) [29]
or through retention of nucleic acid remnants [30] or donor
MHC molecules [31].
The alternative Bsynthetic^ strategy employs non-toxic ma-
terials, such as synthetic polymers, to create an entirely de
280 Curr Stem Cell Rep (2017) 3:279–289
novo scaffold [32]. Scaffolds made in this way are easy to
manufacture and sterilize, carry few ethical concerns sur-
rounding their supply, and they can be built to a patient’s
personal measurements using pre-operative imaging or endo-
scopic examination. Composite scaffolds can be
manufactured to allow separate niches suitable for multiple
cell types within the graft [33]. Moreover, the scaffold mate-
rial can be tailored with interconnected pores or mesh struc-
tures to allow vessel ingrowth and integration [34], and the
scaffold can be decorated with molecular cues to encourage
desirable processes such as angiogenesis. Published work to
date examining the ability of autologous cells to attach to
synthetic material has generally shown these synthetic scaf-
folds to be inferior to biologic scaffolds in this regard [32]. As
a result, considerable efforts are being devoted to optimizing
the production and biocompatibility of synthetic materials for
tissue engineering.
As yet, there is no international consensus on the ideal
biomaterial for supporting tracheal regeneration in vivo [25].
The results of pre-clinical in vivo orthotopic transplantation
studies are difficult to compare between centers due to inevi-
table methodological differences arising from the develop-
ment of these complex procedures. Furthermore, it has proven
difficult to blind researchers to experimental groups in pre-
clinical studies where they are directly compared, given their
drastically different macroscopic and microscopic appear-
ances. This has been a major issue, given the mostly qualita-
tive level of data generated by endoscopic and histological
inspection in most studies.
Published clinical data are limited to single, disparate, case
reports, in which there are often unique and specific confound-
ing issues associated with individual patient’s anatomical
anomalies or co-morbidities. In such reports, it is impossible
to establish a relationship between clinical outcomes and par-
ticular mechanistic processes from the use of specific cells and
scaffolds. However, the synthetic strategy has recently largely
fallen out of favor in Europe and the USA in the light of
concerns raised regarding the conduct of the research reported
in the synthetic case [35, 36]. Reports of poor scaffold inte-
gration parallel findings from other specialties that synthetic
scaffolds used in the mediastinum can migrate to trachea and
or esophagus [37, 38]. Present pre-clinical and clinical trial
efforts in this field thus currently rely on the use of biologic
tissue (decellularized or others, e.g. homografts), and the data
thus far suggest these natural scaffolds exhibit superior safety
and efficacy compared to their synthetic counterparts [20].
Innovative technologies like 3D printing, more reliable ab-
sorbable scaffolds (which are essential in pediatrics to allow
remodeling with growth), and micro-definition of smart poly-
mers containing adhesion molecules and specific growth fac-
tors, may one day allow us to move away from cadaveric
organs and have access to a more reliable, Boff-the-shelf^
technology.
Autologous Cell Choices for Tracheal Regeneration
The main property of an ideal tracheal replacement is the
mechanical ability to withstand collapse under the physiolog-
ical internal and external pressure changes of respiration. In
addition, the proximal airways play an active role as the front-
line defense against inhaled pathogens. The highly specialized
pseudostratified ciliated epithelium, containing cells of both
innate and adaptive immune systems, acts to trap and remove
inhaled pathogens and debris. Overall, the current key goals in
the field of tracheal replacement therapies are (1) to generate
constructs that recapitulate native tracheal biomechanics, (2)
to support a functional mucosa, and (3) to rapidly re-
vascularize to ensure cell survival.While seeded somatic cells
have not been shown to persist long-term within tissue-
engineered grafts after transplantation, they seem to have an
essential role in tissue remodeling and in vivo functional re-
generation [39]. Unseeded scaffolds are more likely to devel-
op strictures, granulations, and leakage and to provoke a local
adverse immune response, which combine to ultimately lead
to failure of the graft [40]. However, for the trachea and other
Bsimple^ hollow organs, it is still not entirely clear which cell
types should be seeded before transplantation to assist func-
tional regeneration of the engineered organ [41•]. This is par-
ticularly important for clinical translation, where the use of
fewer cell types will greatly simplify production, substantially
reduce product costs, and, theoretically, increase patient safety
through facilitating the establishment of robust clinical
manufacturing processes.
Reflective of the tissue composition of the native trachea,
the three most widely studied autologous cell types for trache-
al seeding in the pre-clinical setting (Appendix Table 1) are
mesenchymal stromal/stem cells (MSC), chondrocytes, and
epithelial cells.
Presently, there is no consensus as to the optimal cell and
scaffold combination, as different cell combinations and
seeding strategies have been reported in almost every pre-
clinical and clinical series (Appendix Table 2). We argue that
to accurately conduct these comparisons, it is essential to es-
tablish appropriate in vivo models and for researchers in the
field to reach an agreement as to the most meaningful objec-
tive outcome measures to be evaluated.
Mesenchymal MSCs
Stromal/stem cells (MSCs) are a popular choice for
recellularization in many tissue-engineered organ types [42]
due to their ability to differentiate towards bone, fat, cartilage,
and potentially other lineages [43], their production of wide-
ranging trophic and immunomodulatory factors [44], and their
ease of isolation and ability to be extensively expanded
in vitro [45]. MSCs have predominantly been isolated from
the bone marrow (BM-MSCs) [46], but those from a range of
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tissues, including adipose tissue [47], Wharton’s Jelly [48]
and amniotic fluid [49], have been characterized. Little is
known about human airway-resident MSCs, but human lung
MSCs share a fundamental transcriptional profile with BM-
MSCs, suggesting the latter may well be an appropriate sur-
rogate in tissue engineering applications [50].
MSCs are thought to be somewhat immunoprivileged cells,
and they possess potent immunosuppressive properties, par-
ticularly against allogeneic T cells [51]. These characteristics
have led to the use of allogeneic MSCs in a number of clinical
trials for a variety of therapeutic indications [52] and may also
prove helpful for modulating host cell-mediated degradation
of tissue-engineered scaffolds [53]. Clinical applications of
MSCs have repeatedly demonstrated that these cells are safe
[54]; while there are theoretical safety concerns that implanted
MSCs might give rise to tumors in vivo, no evidence to sup-
port this theoretical risk has ever been seen in any pre-clinical
or clinical assessments of MSCs [14].
There is increasing pre-clinical evidence to support the
benefit of MSC seeding for tracheal tissue engineering, albeit
in relatively small-scale studies. Suzuki et al. compared the
use of allogeneic rat adipose-derived MSC-soaked collagen
sponges compared to collagen alone in the repair of anterior
tracheal defects in rats and found that the inclusion of MSCs
accelerated vascularization and the regeneration of a well-
organized epithelium in 2 weeks [55]. Batioglu-Karaaltin et al.
compared decellularized tracheal transplantation with or with-
out autologous adipose tissue-derived MSCs in rabbits, and
whereas control animals suffered from early fatal graft sepa-
ration, airway stenosis, and infection, animals receivingMSCs
demonstrated only mild to moderate levels of stenosis, with
complete graft integration at 3 months [56]. Clark et al. also
found better integration of MSC-seeded grafts compared to
cell-free control grafts [57]. It is important to note, however,
that although autologous MSCs may be helpful in tissue inte-
gration and revascularization of grafts, they do not represent a
solution for the recurring issues of anastomotic and graft ste-
nosis that can plague orthotopic tracheal replacement [58].
Clinically, MSCs have been used as the main cell type for
pre-implantation seeding in three published cases (one adult
who received a synthetic graft [35, 36] and two children with
decellularized grafts, one of which was prepared to GMP cell
therapy standards) [15, 59••]. The relevance and source of the
cellular contribution to the success of these grafts is difficult to
dissect in the absence of formal clinical trials, so the relation-
ship to pre-clinical studies involving MSCs is not clear.
Chondrocytes
In pre-clinical studies, the most common site for harvesting
differentiated chondrocytes is auricular elastic cartilage
[60–67]. Despite the hyaline nature of tracheal rings, there is
some evidence that the origin of chondrocyte does not affect
the success of tracheal hyaline regeneration in pre-clinical
small patch tracheoplasties [67–69]. Other groups have fo-
cused on the in vitro derivation of chondrocytes from cultures
of MSCs [70, 71]. Embryonic stem cells can also differentiate
into functional chondrocytes, but ethical concerns surround-
ing their use and their capacity for teratoma formation are
significant hurdles to translational use. The ability to obtain
differentiated chondrocytes from patient-specific induced plu-
ripotent stem cells (iPSC) is potentially a more relevant ave-
nue for exploration. Indeed, successful generation of hyaline
cartilage in small animal models has been reported [72, 73].
Unfortunately, protocols for differentiating iPSC to
chondrocytes remain rather limited at present [74, 75].
Outcome measures in studies involving chondrocyte
seeding have included the persistence of chondrocytes within
scaffolds for up to 14 weeks post-operatively [60, 69, 76–80]
and the detection of appropriate extracellular matrix protein
deposition, specifically collagen, elastin, and GAGs [62, 81].
Areas of Bneocartilage^ formation following chondrocyte
seeding have been reported in several small pre-clinical stud-
ies of synthetic [60, 68, 78, 81] and decellularized [70] grafts,
though few of these reports include unseeded control groups,
making data interpretation somewhat difficult. Moreover,
these reports have not included comments on the functionality
of the new cartilage in contributing to the mechanical stability
of grafts, despite the particular relevance of this in studies
where scaffolds are manufactured from biodegradable
material.
In the reported clinical literature, only one patient has re-
ceived decellularized grafts containing chondrocytes derived
from autologousMSCs that were culture expanded and differ-
entiated in vitro [82]. Without deep biopsy of the implanted
grafts, it is not possible to comment on the persistence or
eventual fate of the seededMSCs or chondrocytes nor the role
these cells played in the overall graft success in such patients.
Despite pre-clinical studies [60, 62, 63, 65, 67, 71, 76, 78, 80,
81, 83–86], to our knowledge, there have been no clinical
reports of the use of harvested differentiated chondrocytes in
tracheal tissue engineering.
Epithelial Cells
Since MSCs are stromal and do not differentiate towards re-
spiratory epithelial cells, they cannot restore barrier function
or contribute directly to the regeneration of the mucociliary
epithelium in tracheal grafts. Hence, many groups have inves-
tigated the possibility of enhancing tracheal regeneration by
seeding the scaffolds with epithelial cells. A few pre-clinical
studies have examined luminal epithelial cell seeding in the
absence of other cell types [58, 87], but poor graft epithelial-
ization was reported to lead to premature death from mucus
plugging, pneumonia, or graft infection in the few studies in
which epithelial cells were not co-seeded with MSCs [70, 83].
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The restoration of a functional epithelium is clearly dependent
on the surface area of coverage required. Short length or par-
tial circumference grafts have been shown to epithelialize
more quickly in both pre-clinical and clinical contexts, prob-
ably from ingrowth from the anastomotic margins [57, 86,
88–92]. In rabbit models, where the required surface area of
an anterior graft is usually less than 5 cm2, epithelialization of
grafts from anastomotic ingrowth has been reported to be
underway by 2 weeks [93] and to be completed by 10–
14 weeks [80, 94].
The rationale for including epithelial cells in tissue engi-
neering approaches for the trachea is twofold. The first is to
mediate long-term regeneration of the airway epithelium di-
rectly through engraftment. In some clinical cases, it has been
practical to expand autologous airway epithelial cells in cul-
ture [35, 36, 59••, 95] or to include explant biopsies within
grafts [15]; however, based on the length of time taken for
epithelial regeneration in these patients [14, 96], now thought
that the seeded epithelial cells were unlikely to have contrib-
uted to epithelial restoration. This is likely explained by the
need for a vascular supply to be established prior to successful
epithelial cell seeding, a hypothesis supported by the greater
epithelialization in some pre-clinical studies employing pe-
riods of heterotopic pre-vascularization prior to orthotopic tra-
cheal replacement [58, 60, 83]. Most clinical cases report the
epithelialization process can take up to 2 years in segmental
grafts, during which time patients remain vulnerable to mucus
plugging and graft infection unless they receive frequent, in-
convenient, and uncomfortable cleaning by bronchoscopy
[15]. The presence of fibroblasts, known to improve epithelial
survival and culture in vitro [97, 98], has been suggested to
expedite this process in some in vivo animal studies in small
sections of grafts [68, 76, 99–101]. It is hoped that improved
understanding of human airway epithelial stem cell biology
and robust techniques to apply cultured epithelial cells to
grafts will ultimately move the field forward sufficiently to
allow the development of epithelial cell therapies that are able
to contribute directly to long-term regeneration.
The second argument for including epithelial cells is that
these cells could be employed as a biological dressing, pro-
viding barrier function and signals to enhance local regenera-
tion, rather than being required to engraft long term and con-
tribute to tissue regeneration. Delaere and colleagues
employed buccal mucosa grafts to cover the luminal surface
of pre-implanted tracheal transplants following the degenera-
tion of the donor mucosa on withdrawal of immunosuppres-
sion [102, 103]. While these cells are unlikely to
transdifferentiate to produce ciliated epithelium, this mucosal
source could prove helpful to create a temporary barrier to
infection in extensive grafts, pending regeneration of respira-
tory mucosa from the anastomotic margins. Indeed, there is
evidence from epidermal transplantation that such a
Bbiologically active dressing^ approach, using allogeneic
[104] or even lyophilized [105] epithelial cells, can stimulate
regeneration from surrounding host cells.
Cell Seeding Considerations
It stands to reason that, given the complexity of the native
trachea, it is likely that multiple cell types need to be present
in an optimized bioengineered tracheal transplant. Since
MSCs aid appropriate proliferation and differentiation of other
cell types, such as chondrocytes [106], in vitro and also aid the
migration of endogenous epithelium to cover grafts [107],
they are a prime candidate for co-seeding strategies. Haykal
et al. reported that the dual application of autologous MSCs
and tracheal epithelial cells in a heterotopic pig model helped
to preserve cartilage within decellularized tracheal matrix,
where the MSCs evoked an immunomodulatory response,
increasing the numbers of infiltrating regulatory T cells, as
compared to decellularized matrix alone [108]. Tsao et al.
co-transplanted chondrocytes and MSCs and found the depo-
sition of type II collagen within biodegradable synthetic tra-
cheal grafts was higher in co-transplanted animals than in
animals receiving a single cell type or no cells [83]. In another
study, Go et al. found that animals receiving decellularized
grafts that were seeded with both chondrocytes and epithelial
cells had lower levels of graft stenosis and bacterial contami-
nation and increased overall survival compared to animals
receiving bare or single cell type-seeded scaffolds [70].
Based on these preclinical studies showing a benefit for
seeding with more than one cell type, many of the clinical
cases reported to date have aimed to co-seed distinct external
and luminal cell types [15, 35, 36, 59••, 92, 95].
The interpretation of data concerning the ideal cell type(s)
to be included in tissue-engineered grafts is hampered by the
lack of studies that have investigated critical variables such as
the numbers of cells seeded or the methods used to propagate
the cells ex vivo. As a result, the number of MSCs or
chondrocytes required, the optimal techniques used to apply
them to the scaffold to achieve seeding Bsuccess,^ and the
parameters by which Bsuccess^ can be judged all remain un-
clear. When surveying the existing literature, the reported
scaffold cell seeding density varies widely (for example, a
range of 1 × 106 cells/ml [109] to 5 × 1010 cells/ml [57] for
bone marrow MSCs), and repeated or sequential seeding of
scaffolds has rarely been attempted. Additionally, significant
variation in cell seeding efficiency may further impact the
final number of cells surviving and the type of cells present
within scaffolds at the point of implantation [57]. For epithe-
lial cells, in vitro data suggest that over 1 × 106/cm2 human
airway epithelial cells are required for uniform seeding of
decellularized tracheal grafts when seeding from a cell sus-
pension, suggesting that the clinically applied protocol using
serum-free growth medium may be inadequate to generate
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sufficient cell numbers for long-segment human grafts [110].
While most studies to date have involved seeding cultured
cells onto biomaterials as a cell suspension, this approach
may need to be reconsidered in the case of the epithelium,
where precedent from epidermal and corneal transplantation
indicates the superiority of cultured cell sheets and the impor-
tance of stem cell retention during culture [111].
Technologies such as custom-designed bioreactors have
been utilized in an effort to improve the efficacy of ex vivo
seeding, including coverage, migration, and proliferation [35,
36, 59••, 82, 92]. These systems typically allow for separate
seeding and media flow for extraluminal and intraluminal
compartments [70, 109]. Most groups employing bioreactor
systems have reported that optimal seeding occurs with a pe-
riod of initial static seeding to allow cells to adhere to the
scaffold surface, followed by a variable length of time with
dynamic movement of either the graft, media, or both [56, 66,
67, 71, 86, 107]. However, to date, these in vitro parameters
do not seem to necessarily translate to cell retention or demon-
strable improvements in in vivo outcomes.
The degree to which the benefits of cell-seeded grafts are
due to direct cell engraftment and retention versus the effect of
the release of both free and exosome-contained chemotactic
and trophic factors [112] from these cells remains unclear. In a
subcutaneous heterotopic tracheal allograft model, it has been
reported that repeated doses of MSCs might be effective in
reducing both fibrosis and the extent of immune infiltrate,
despite the failure of MSCs to persist long term within the
scaffolds following implantation [113]. In these circum-
stances, signals might provide a stimulus for regeneration
through immune modulation or by host cell recruitment.
Graft Vascularization
Establishment of a blood supply is essential for any graft to
permit the supply of nutrients to seeded cells and to native/
endogenous cells growing into the tissue-engineered organ. A
major surgical hurdle to tracheal replacement is that, unlike
solid organs such as the kidney or lobes of the liver, there is no
discrete blood supply that feeds the trachea; instead, the tra-
chea relies on a finely segmental native blood supply, rather
than a vascular pedicle that would be amenable to anastomo-
sis. Bioengineered tracheal grafts are, therefore, relatively
slow to establish vascular connections capable of supporting
cell growth and tissue integration. The use of a period of
heterotopic vascularization elsewhere in the body, prior to
tracheal transfer as a pedicled or free flap transfer, has been
shown to generate a clinically significant blood supply [60,
102]. Such a strategy may take several weeks––or even
months––to become established and is therefore not possible
in emergency situations. In such cases, an interposition graft
or omental/pericardial vascularized wrap may be performed at
the time of surgery, if such tissue is available [15, 91]. Pre-
seeded cells may not survive the vascularization period, so
delayed and/or multiple post-operative cell applications could
be considered. Interestingly, autograft experiments in which
animal tracheae have been removed (and in so doing,
devascularized), inverted, and returned to the animal have
resulted in minimal morbidity [114, 115], implying that the
lack of a vascular pedicle is not necessarily a barrier to success
if one can generate an optimized tracheal tissue-engineered
scaffold.
Limitations of Current Data
The pre-clinical and clinical literature regarding cell seeding
in tracheal tissue engineering is a highly heterogeneous mix of
experimental designs and outcome measures, which makes it
difficult to provide clear recommendations for future autolo-
gous cell strategy choices. The pre-clinical studies identified
here have often relied upon qualitative outcome measures
such as histology, endoscopic observation, or the presence or
absence of gross complications, rather than attempting to
quantify cell retention, survival, or the differentiation of cells
within the grafts. In addition to these limitations, there is rarely
any mention in the literature as to blinding of either surgeons
or researchers to the presence or absence of cells, or to ran-
domization of animals. A particular challenge is demonstrat-
ing that cells found at post-mortem or biopsy are indeed those
that were seeded pre-operatively, without some form of cell
labeling to allow tracking. While transfection of cells to ex-
press a fluorescent protein [55, 66, 68, 99, 107, 109, 116] or
the use of cell membrane dyes [83] has facilitated the tracking
of seeded cells in some studies, these approaches do not rule
out false-positive signals from dead, phagocytosed, or fused
cells within the graft. Incorporation of luciferase into seeded
cells––and the use of its substrate luciferin to generate a bio-
luminescent signal––would provide more compelling data, as
this reaction can only occur in living cells [117].
Unfortunately, bioluminescence imaging is practically diffi-
cult in the medium to large animals that are most amenable
to orthotopic transplantation and is certainly not practicable in
human patients.
Care must be taken in assessing studies where small or only
partial circumference grafts are employed, as ingrowth from
endogenous tissue may lead to the over-reporting of benefit.
Extrapolating such findings tomodel longer-segment segmen-
tal grafts, where circumferential granulation and stenosis re-
main unresolved hurdles in both pre-clinical and clinical sce-
narios [14], may not prove to be appropriate.
While the evolution of pre-clinical surgical techniques can
be seen in many cases to model, as closely as possible, the
clinical scenario in terms of endoscopic intervention and stent
placement [65, 81, 118], it is still impractical to provide the
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level of intensive airway support and round-the-clock surveil-
lance possible in a human intensive care setup. Most studies
employ low numbers of individual animals in each experi-
mental arm, and in many cases, a cell-free control arm has
not been included. While this may represent well-meaning
literal interpretation of the ethical pillars of animal research,
namely to reduce the numbers of animals used as much as
possible [119], the lack of inclusion of well-designed control
groups greatly complicates meaningful analysis of results,
given how many complex factors are in play in vivo. While
seeded tracheal tissue-engineered grafts have been reported to
outperform unseeded grafts in several pre-clinical studies [55,
56, 58, 70, 79, 80, 83, 100, 107, 116, 120], the most useful
control arm to include to answer this question would be a
scaffold with cell-conditioned medium only (given the wealth
of growth factors present within most media). In addition,
despite showing great promise, only a minority of pre-
clinical studies have investigated and reported on the use of
multiple cell types within the graft [70, 76, 83, 84, 99, 100].
Thoughtful and systematic experimental design of further
animal studies will be vital to allow the testing of cell types
and combinations, ratios, and seeding timings as objectively
as possible [121]. In the clinical scenario, it is vital that inter-
national groups working in this field report their outcomes in
as transparent a manner as possible, both to secure public trust
in the integrity of the field and to allow groups who are un-
dertaking such compassionate use treatments elsewhere to
learn from their experiences [122•].
舃Key proposals for international debate
舃1. Limited menu of pre-clinical animal in vivo experimental designs
舃2. Standard definitions of cells, and scaffolds and key criteria for
reporting on results
舃3. Randomization and blinding of in vivo experimental and control
arms
舃4. Internationally agreed objective outcome measures, e.g.,
epithelialization, functional cartilage formation, or degree of stenosis
舃5. International transparent register of tracheal tissue engineering
clinical cases
Conclusion
The incorporation of recipient cells into tissue-engineered tra-
cheal replacement therapies appears crucial for graft survival
and, once optimized, the inclusion of exogenous cells could
directly improve graft functionality. While there is evidence
that seeding of tracheal grafts with autologous cells is benefi-
cial overall, particularly with regard to the use of MSCs, it is
still unclear which specific cell types and combinations are
optimal for promoting regeneration. Further, there are funda-
mental questions that remain unanswered regarding the
optimal cell type(s) and seeding strategies in this context. It
is clear that future pre-clinical studies should undergo rigorous
and systematic experimental design to maximize the genera-
tion of clinically useful data regarding the roles of seeded
cells, particularly with respect to graft mechanical stability,
cartilage maintenance, epithelialization, stenosis, and
vascularization.
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